Unique ID issued by UMIN | C000000042 |
---|---|
Receipt number | R000000082 |
Scientific Title | A phase II study of percutaneous trans-esophageal gastric tubing for malignant gastrointestinal obstruction (JIVROSG-0205) |
Date of disclosure of the study information | 2005/08/06 |
Last modified on | 2010/02/11 14:27:02 |
A phase II study of percutaneous trans-esophageal gastric tubing for malignant gastrointestinal obstruction (JIVROSG-0205)
Percutaneous trans-esophageal gastric tubing (JIVROSG-0205)
A phase II study of percutaneous trans-esophageal gastric tubing for malignant gastrointestinal obstruction (JIVROSG-0205)
Percutaneous trans-esophageal gastric tubing (JIVROSG-0205)
Japan |
Malignant gastrointestinal obstruction
Gastroenterology | Hepato-biliary-pancreatic medicine | Hematology and clinical oncology |
Gastrointestinal surgery | Hepato-biliary-pancreatic surgery | Breast surgery |
Obstetrics and Gynecology | Radiology |
Malignancy
NO
To evaluate the safety and efficacy of percutaneous trans-esophageal gastric tubing for malignant gastrointestinal obstruction.
Efficacy
Confirmatory
Explanatory
Phase II
Improvement of subjective symptoms compared to previous nasal tubing.
Adverse events and feasibility of procedure
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Maneuver |
Under local anesthesia and fluoroscopy or ultrasonic guidance, a percutaneous route to cervical esophagus is made by direct puncture to the intra-esophageal balloon inserted via nasal or oral route, and then, a drainage tube is placed from the neck surface to the stomach using this route.
Not applicable |
Not applicable |
Male and Female
1) No expectation for removal of nasal tube caused by persistent and malignant gastro-intestinal obstruction.
2) No pathological condition around cervical esophagus.
3) Adequate cardiac, hepatic, renal, respiratory, and bone marrow functions.
4) Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 3.
5) Expected survival more than 4 weeks.
6) Written informed consent.
1) Tracheostomy.
2) Intestinal obstruction due to the lesions between transverse colon and rectum.
3) Pregnancy.
4) Local therapy for neck region
33
1st name | |
Middle name | |
Last name | Takeshi Aramaki |
Shizuoka Cancer Center
Department of Imaging Diagnosis
1007, Shimonagakubo, Nagaizumi-cho, Shuntoh-gun, Shizuoka 411-8777, Japan
055-982-5222
1st name | |
Middle name | |
Last name | Yasuaki Arai |
JIVROSG, Coordinating Office
Division of Diagnostic Radiology, National Cancer Center Hospital
5-1-1,Tsukiji,Chuo-ku,Tokyo,104-0045,Japan
03-3542-2511
http://jivrosg.umin.jp/
jivrosgoffice@ml.res.ncc.go.jp
Japan Interventional Radiology in Oncology Study Group (JIVROSG)
Ministry of Health, Labour and Welfare
Japan
NO
2005 | Year | 08 | Month | 06 | Day |
http://jivrosg.umin.jp/
Unpublished
Technical success rate: 100%
Average required time for procedure: 28.5 min
Clinical efficacy: 91%
Mortality within 30 days: 5 (All caused by progression of primary disease)
Procedure related Adverse events (>Grade 2): Broncho-esophageal fistula
Completed
2002 | Year | 11 | Month | 30 | Day |
2003 | Year | 07 | Month | 01 | Day |
2006 | Year | 03 | Month | 01 | Day |
2006 | Year | 06 | Month | 01 | Day |
2006 | Year | 06 | Month | 01 | Day |
2006 | Year | 10 | Month | 01 | Day |
2005 | Year | 08 | Month | 06 | Day |
2010 | Year | 02 | Month | 11 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000000082